GM-CSF was not superior to the conventional mouthwash in terms of oral mucositis, pain perception, the incidence of secondary infection, or hematological abnormalities. Therefore, topical GM-CSF was not recommended for the treatment of chemoradiotherapy-induced oral mucositis in patients with head and neck cancer. This evidence concerns the gene CSF2 and head and neck cancer.